MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 333085 | Name: Povorcitinib phosphate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Povorcitinib (also known as INCB54707) is an oral, selective Janus kinase 1 (JAK1) inhibitor under investigation for various inflammatory and autoimmune conditions. It demonstrates high potency and selectivity for JAK1 over other JAK isoforms, with reported IC₅₀ values of 58 nM for JAK1, compared to 487 nM for JAK2 and >1,000 nM for JAK3 in biochemical assays. In cellular models, povorcitinib effectively inhibits cytokine-induced STAT phosphorylation, including IFN-α and IL-6 signaling pathways, indicating strong suppression of JAK1-dependent immune responses.

Chemical Structure

Povorcitinib phosphate
Povorcitinib phosphate
CAS#1637677-33-8 (phosphate)

Theoretical Analysis

MedKoo Cat#: 333085

Name: Povorcitinib phosphate

CAS#: 1637677-33-8 (phosphate)

Chemical Formula: C23H25F5N7O5P

Exact Mass: 0.0000

Molecular Weight: 605.46

Elemental Analysis: C, 45.63; H, 4.16; F, 15.69; N, 16.19; O, 13.21; P, 5.12

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
1637677-22-5 (free base) 1637677-33-8 (phosphate)
Synonym
Povorcitinib phosphate; Povorcitinib; INCB54707; INCB-54707; INCB 54707;
IUPAC/Chemical Name
(S)-4-(3-(cyanomethyl)-3-(3',5'-dimethyl-1H,1'H-[4,4'-bipyrazol]-1-yl)azetidin-1-yl)-2,5-difluoro-N-(1,1,1-trifluoropropan-2-yl)benzamide phosphate
InChi Key
XUQIWHXYCLHHCN-UQKRIMTDSA-N
InChi Code
InChI=1S/C23H22F5N7O.H3O4P/c1-12-20(13(2)33-32-12)15-8-30-35(9-15)22(4-5-29)10-34(11-22)19-7-17(24)16(6-18(19)25)21(36)31-14(3)23(26,27)28;1-5(2,3)4/h6-9,14H,4,10-11H2,1-3H3,(H,31,36)(H,32,33);(H3,1,2,3,4)/t14-;/m0./s1
SMILES Code
O=C(N[C@@H](C)C(F)(F)F)C1=CC(F)=C(N2CC(N3N=CC(C4=C(C)NN=C4C)=C3)(CC#N)C2)C=C1F.O=P(O)(O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 605.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kirby JS, Okun MM, Alavi A, Bechara FG, Zouboulis CC, Brown K, Santos LL, Wang A, Bibeau KB, Kimball AB, Porter ML. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo- controlled study. J Am Acad Dermatol. 2024 Mar;90(3):521-529. doi: 10.1016/j.jaad.2023.10.034. Epub 2023 Oct 21. PMID: 37871805. 2: Müller S, Zeidler C, Ständer S. Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments. Am J Clin Dermatol. 2024 Jan;25(1):15-33. doi: 10.1007/s40257-023-00818-z. Epub 2023 Sep 17. PMID: 37717255; PMCID: PMC10796623. 3: Thünemann J, Müller S, Steinbrink K, Ständer S, Zeidler C. Chronic Prurigo. J Dtsch Dermatol Ges. 2024 Jun;22(6):813-823. doi: 10.1111/ddg.15317. Epub 2024 May 9. PMID: 38722190. 4: Liao V, Cornman HL, Ma E, Kwatra SG. Prurigo nodularis: new insights into pathogenesis and novel therapeutics. Br J Dermatol. 2024 May 17;190(6):798-810. doi: 10.1093/bjd/ljae052. PMID: 38345154; PMCID: PMC11099982. 5: Liu H, Santos LL, Smith SH. Modulation of Disease-Associated Pathways in Hidradenitis Suppurativa by the Janus Kinase 1 Inhibitor Povorcitinib: Transcriptomic and Proteomic Analyses of Two Phase 2 Studies. Int J Mol Sci. 2023 Apr 13;24(8):7185. doi: 10.3390/ijms24087185. PMID: 37108348; PMCID: PMC10139090. 6: Miller A, Shahzeidi P, Bernhardt M. An Update on Current Clinical Management and Emerging Treatments in Hidradenitis Suppurativa. Skin Therapy Lett. 2024 Mar;29(2):1-6. PMID: 38574201. 7: Heidari A, Ghane Y, Heidari N, Sadeghi S, Goodarzi A. A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for Hidradenitis suppurativa treatment. Int Immunopharmacol. 2024 Jan 25;127:111435. doi: 10.1016/j.intimp.2023.111435. Epub 2023 Dec 26. PMID: 38150881.